Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

KCL-HO-1i

Name: KCL-HO-1i
Brand: TargetMol
SKU: T213178
Rating: 4.5 (1 reviews)

Catalog No. T213178 Copy Product Info

🥰Excellent

KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor with an IC50 of 123 nM for rat HO-1 and 128 nM for human HO-1. It targets immune-suppressive LYVE-1+ perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME) and reduces PvTAM-mediated immune evasion. In MMTV-PyMT mice with spontaneous breast cancer or C57Bl/6 mice with subcutaneous MN-MCA1 sarcoma, KCL-HO-1i demonstrates synergistic anti-tumor effects when combined with chemotherapy. It is applicable for cancer research.

KCL-HO-1i

Copy Product Info

🥰Excellent

Catalog No. T213178

KCL-HO-1i

Pack Size	Price	USA Stock	Global Stock	Quantity
10 mg	Inquiry	Inquiry	Inquiry
50 mg	Inquiry	Inquiry	Inquiry

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Resource Download

Product Introduction

Bioactivity

Description	KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor with an IC50 of 123 nM for rat HO-1 and 128 nM for human HO-1. It targets immune-suppressive LYVE-1+ perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME) and reduces PvTAM-mediated immune evasion. In MMTV-PyMT mice with spontaneous breast cancer or C57Bl/6 mice with subcutaneous MN-MCA1 sarcoma, KCL-HO-1i demonstrates synergistic anti-tumor effects when combined with chemotherapy. It is applicable for cancer research.
Targets&IC50	HO-1:123 nM (rat splenic microsomes)
In vitro	KCL-HO-1i exhibits inhibitory activity in rat spleen microsomes against rat heme oxygenase-1 (HO-1) with an IC50 of 123 nM and demonstrates similar effects in HEK293T cells with an IC50 of 128 nM. At a concentration of 25 μM over 16 hours, KCL-HO-1i enhances the transendothelial migration of CD8+ T cells, reversing migration limitations caused by IL-6-polarized bone marrow-derived macrophages in transwell assays.
In vivo	KCL-HO-1i administered alone at 27.8 mg/kg (25 μMol/kg) orally once daily for 21 days can slow tumor growth. It also works synergistically with chemotherapy (5-fluorouracil or Gemcitabine) to achieve sustained tumor growth control in MMTV-PyMT spontaneous mammary tumor mice and C57Bl/6 mice with subcutaneous MN-MCA1 sarcomas.

Chemical Properties

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc